Genomics
PrivateA de-risked-balance-sheet, left-for-dead cardiac gene-therapy optionality trade — market ascribes ~$60-100M EV to a first-approved product + late-stage Danon program funded into Q2 2028; the whole thesis is one 2H-2026 Danon Phase 2 safety readout after a trial death, and that readout is genuinely binary.
Research
The verdict
A de-risked-balance-sheet, left-for-dead cardiac gene-therapy optionality trade — market ascribes ~$60-100M EV to a first-approved product + late-stage Danon program funded into Q2 2028; the whole thesis is one 2H-2026 Danon Phase 2 safety readout after a trial death, and that readout is genuinely binary.
Primary sources
Source documents — open to read in full
Business model. Rocket is a pre-revenue, fully-integrated gene-therapy developer — it discovers, manufactures (in-house cGMP), and seeks to commercialize genetic medicines for rare, often-fatal monogenic diseases. It has no product revenue: "We have not generated any revenue and have incurred losses since inception". Revenue, if it ever comes, is ultra-rare-disease drug sales (six-to-seven-figure one-time gene therapies to tiny patient populations) plus non-dilutive monetization events (grants, priority-review-voucher sales).
Two technology platforms:
What actually changed the company (July 2025 strategic reorganization): concentrate resources on AAV cardiovascular; de-prioritize FA + PKD (now seeking external partners for those); 30% RIF; ~25% cut in 12-month opex. This is a classic "runway-extension survival pivot" after a clinical crisis.
Customers / suppliers / structure. No commercial customers yet. KRESLADI's route to market is a vein-to-vein autologous logistics chain — treatment-center onboarding, HSC collection, LV modification, reinfusion — for an "exceptionally small patient population" with a "phased commercial rollout" and "no material revenue in the near term". customers.csv is empty — correct, there are none. Key suppliers are the academic/institutional IP licensors (CIEMAT Group, UCSD, RegenXBio/RGNX, Temple University, UCL Business) to whom Rocket owes royalties (low-single to low-teens %) and milestone payments.
Payment terms of note. All the pipeline IP is licensed-in and royalty-bearing, not fully owned — e.g. the Danon AAV9 vector is licensed from RegenXBio with high-single-to-low-teens royalties + up to $13M milestones per product + 20% of any priority-review-voucher proceeds payable to RGNX. That RGNX 20%-of-PRV clause is a real, quantified drag — see Lens 10.
The "supply chain" for a gene-therapy developer is its manufacturing + input + clinical-trial-execution chain. Named stakeholders along it:
Chokepoints / single-source dependencies: (1) the Cranbury plant is the sole manufacturing node — an FDA facility action would halt everything; (2) the immunomodulation protocol is the recurring clinical-safety chokepoint for the entire AAV cardiac platform (a Danon problem is a platform problem because RP-A601 and RP-A701 use related regimens); (3) licensed-in IP means the "supply" of legal freedom-to-operate depends on academic licensors maintaining patents.
For a clinical-stage gene-therapy microcap, "moat" means: can it be first, and can it stay first once approved?
Bargaining power: weak as a supplier (ultra-rare populations, payors will negotiate hard on a one-time high-cost therapy), and dependent on academic licensors upstream. The real power is scientific — if the Danon data hold, Rocket owns the only curative option and payors have no substitute.
Bottom line on moat: the moat is real but entirely contingent on the science working. A microcap with an approved orphan drug and an only-in-class late-stage asset has a genuine moat; a microcap whose lead asset just killed a patient has a moat that could evaporate on the next safety readout. This is a fragile, binary moat — not a compounding one.
segments.csv is empty and correctly so — Rocket reports as one segment / one reporting unit. There is no revenue to disaggregate (revenue = $0 in both FY2025 and Q1-2026 ). The economically meaningful "segmentation" is by platform and program, which is captured in the Lens 5 pipeline table. Geographically, trials run across the U.S. and EU; commercialization of KRESLADI will be U.S.-first. No segment-level P&L exists to trend.
The asset table is the company. Every program as a row:
| Program | Indication (modality) | Prevalence (US+EU) | Phase / status | Key designations | Next value-inflection |
|---|---|---|---|---|---|
| RP-A501 (lead) | Danon disease — LAMP2 (in vivo AAV9, IV) | 15,000–30,000 | Pivotal Phase 2 — resumed dosing Q1-2026 at recalibrated 3.8e13 GC/kg after clinical hold | RMAT, Fast Track, Rare Pediatric, Orphan (US); ATMP, PRIME (EU) | Program update 2H-2026 on first 3-patient re-dosed cohort |
| KRESLADI (RP-L201, marnetegragene autotemcel) | Severe LAD-I (ex vivo LV, autologous HSC) | several hundred cases | APPROVED — FDA accelerated approval Mar 27, 2026 | RMAT, Rare Pediatric, Fast Track (US); PRIME, ATMP (EU) | Commercial launch (phased); confirmatory follow-up for full approval |
| RP-A601 | PKP2-ACM (in vivo AAVrh74, IV) | ~50,000 | Phase 1 ongoing (3 patients dosed); dose selected 8e13 GC/kg | RMAT, Fast Track (US); Orphan (US+EU) | Pivotal Phase 2 design alignment with FDA |
| RP-A701 | BAG3-DCM (in vivo AAVrh74, IV) | ~30,000 | Phase 1 — IND cleared June 2025, Fast Track July 2025; first-in-human dose-escalation | Fast Track (US) | First patient dosing / initial safety |
| RP-L102 | Fanconi Anemia (ex vivo LV) | 5,500–7,000 (addressable now ~400–500/yr) | De-prioritized — no further internal BLA/EMA work; seeking partner | RMAT, Rare Pediatric, Fast Track; PRIME, ATMP; Orphan | Out-licensing only |
| RP-L301 | PKD (ex vivo LV) | 4,000–8,000 | De-prioritized — Phase 2 designed but not initiated; seeking partner | RMAT, Fast Track; PRIME; Orphan | Out-licensing only |
Lead-asset data (RP-A501 Phase 1, the reason to believe): all evaluable Danon patients showed cardiac LAMP2 protein expression at 12 months (sustained up to 60 months); median LVMI reduction 24% from baseline; preserved LVEF; median cardiac troponin I / BNP reductions of 84% / 57%; NYHA improved Class II→I; median KCCQ-12 improvement of 27 points persisting to 54 months. Published in NEJM (Nov 2024). This is described as "one of the first and most comprehensive investigational gene-therapy datasets for any cardiac condition."
The safety break (the whole story): In May 2025, two Phase 2 patients had unexpected SAEs — capillary leak syndrome → multi-organ damage; one patient died following an acute systemic infection. FDA clinical hold May 23, 2025. Investigation concluded the SAEs were "likely the result of the combination of the C3 component inhibitor introduced into the immunomodulation regimen and RP-A501." Hold lifted Aug 20, 2025; trial resumed at a lower recalibrated dose (3.8e13 GC/kg), first three patients dosed sequentially ≥4 weeks apart, with the C3 inhibitor implicated component addressed. Six patients total have now been treated in the Phase 2. The forward catalyst is the 2H-2026 update on the re-dosed cohort.
Financial print (context, since there is a P&L shell): Q1-2026 revenue $0; R&D $31.5M (−$4.5M YoY), G&A $17.1M (−$11.4M YoY — restructuring landing), total opex $48.5M, net loss $47.6M (−$0.42/sh) vs $61.3M prior-year quarter. FY2025: net loss $223.1M (FY24 $258.7M); R&D $142.0M, G&A $86.5M, restructuring $3.2M; SBC $37.1M. The trend is a deliberately shrinking cost base — burn is being managed down, not up (unusual and healthy for the pivot).
Balance sheet (the reason it's still alive): Cash + investments $144.4M at Mar 31, 2026; pro-forma ~$322.6M after the $180M PRV close (June 12, 2026). Accumulated deficit $1.489B. Total debt = only a ~$21.3M finance lease on the Cranbury plant — no meaningful financial debt. Total equity $238.0M; APIC $1.726B. Runway guided into Q2 2028.
transcripts/ is empty on the shelf; this lens is `` + the filings' MD&A narrative. Management's messaging arc over the last ~4 quarters is a clear, traceable shift:
Recurring phrases now: "fully integrated commercial-stage," "prioritized cardiovascular gene therapy pipeline," "non-dilutive capital," "phased commercial rollout." Things they stopped saying: the broad multi-indication ambition (FA/PKD "cures for all") — those are now "exploring external partnership options." The narrative compressed from platform-story to one-asset-plus-a-fortress-balance-sheet story.
Catalyst calendar (what de-risks or kills each program, and when):
| Catalyst | Program | Window | Why it matters |
|---|---|---|---|
| Danon Phase 2 program update (first re-dosed cohort) | RP-A501 | 2H-2026 | THE binary. Clean safety at 3.8e13 + confirmed biomarker efficacy = re-rate; another SAE = thesis breaks and platform doubt spreads to A601/A701 |
| KRESLADI commercial ramp | RP-L201 | 2026-2027 | Optionality; management guides no material near-term revenue — do NOT underwrite meaningful sales |
| RP-A601 (PKP2-ACM) pivotal Phase 2 design/FDA alignment | RP-A601 | 2026 | Next cardiac asset; Phase 1 showed PKP2 expression +110%/+398% in low-baseline patients, no dose-limiting tox |
| RP-A701 (BAG3-DCM) first patient dosing / initial safety | RP-A701 | 2026-2027 | Earliest-stage; platform-breadth signal |
| FA / PKD partnering | RP-L102 / RP-L301 | opportunistic | Non-dilutive upside; not core |
Mechanism / peer comps (there are no earnings multiples for a $0-revenue name; peers are by stage and modality, valuations ``). Market caps as of ~mid-2026:
| Company | Ticker | Modality / focus | Approx. mkt cap | Note |
|---|---|---|---|---|
| Rocket Pharma | RCKT | AAV cardiac GT + LV hematology; 1 approved | ~$360M | Trades near net cash; ~$322.6M pro-forma cash |
| Krystal Biotech | KRYS | Redosable AAV (VYJUVEK approved, profitable) | ~$8B+ | The "it worked" outcome — $730M+ cumulative VYJUVEK sales |
| Sarepta | SRPT | AAV DMD (Elevidys) | EV/Sales ~1.0 | The "approved but troubled" cautionary comp |
| Tenaya | TNYA | AAV cardiac (HCM, ARVC) | small-cap | Direct cardiac-GT peer; competes with RP-A601 in PKP2 |
| Lexeo | LXEO | AAV cardiac (Friedreich ataxia) | small-cap | Cardiac-GT peer; former litigation counterparty (settled June 2025) |
| uniQure / Taysha | QURE / TSHA | AAV (Huntington's / CNS) | small/mid-cap | Broader AAV comp set |
Standard EV/Sales, P/E, EV/EBIT, dividend yield, 5-yr ROE: n/a / not meaningful (RCKT has no revenue, no earnings, no dividend, and a deeply negative ROE by construction). The only defensible cross-read is that Rocket trades at a fraction of Krystal's approved-asset valuation and roughly in line with the distressed end of the cardiac-GT peer group, consistent with the post-death overhang.
The RCKT tape is almost entirely binary-event-driven, which itself is the key market-behavior finding:
What the market actually reacts to for this name: clinical-trial safety events and regulatory binaries — not financials, not KRESLADI economics. The Dec-2024 equity raise ($182.5M at $12.50) and the balance-sheet strengthening barely register in the price. The pattern says the 2H-2026 Danon safety update will be the next ≥5% (likely ≥25%) move, in either direction.
Acting as a forensic analyst on a pre-revenue biotech — the risk vectors differ from an operating company.
Regulatory findings (required sub-section):
No EPS model — this is a +clinical name. The two questions that matter:
(1) Does cash runway reach the next value-inflection catalyst? Yes, comfortably. Pro-forma cash ~$322.6M vs a falling burn (~$40–48M/quarter post-restructuring; FY25 op cash burn $190M ≈ $47.5M/qtr, Q1-2026 opex $48.5M and dropping) funds operations into Q2 2028 per company guidance. The 2H-2026 Danon update, the RP-A601 pivotal-design decision, and RP-A701 first-in-human all sit well inside the runway. Runway is no longer the risk — a rarity for a post-crisis microcap.
(2) Rough rNPV framing of the lead asset (all inputs ``, illustrative — not a forecast):
Brier forecast to log (illustrative, not committed in --watchlist): "RCKT — RP-A501 Danon Phase 2 first re-dosed cohort reports no treatment-related death/serious complement SAE by 2026-12-31, p≈0.60." (Not logged — watchlist loop skips forecast.ts create.)
Bull case. Rocket is a de-risked-balance-sheet option on a binary catalyst that the market has left for dead. (1) ~$322.6M pro-forma cash, no real debt, runway to Q2 2028 — it does not need to raise into the catalyst, removing the classic microcap death-spiral. (2) First approval already banked (KRESLADI) — the platform can clear FDA, and the accompanying PRV was monetized for $180M, a repeatable non-dilutive engine as more programs approve. (3) The Danon Phase-1 efficacy signal is genuinely strong and NEJM-published (24% median LVMI reduction, 84%/57% biomarker drops, +27 KCCQ, durable to 54–60 months) — this is not a hope-and-prayer asset, it's an asset with a mechanistic problem that was identified and removed (the C3 inhibitor). (4) Only-in-class in a fatal orphan disease — if it works, there is no substitute and pricing power is real. (5) At ~$3.33 the stock is barely above ~$2.75 net cash/share, so a clean 2H-2026 readout could re-rate hard while downside is cushioned.
Bear case (permanent-impairment risks). (1) Another safety event. The lead asset already killed a patient; capillary-leak/complement toxicity in systemic high-dose AAV is a known, dangerous failure mode, and a second serious SAE in the re-dosed cohort would likely be terminal for the Danon program and cast doubt across the entire AAV cardiac platform (A601, A701 use related regimens) — this is a genuine permanent-impairment scenario. (2) The lower recalibrated dose may not be efficacious enough — cutting the dose to fix safety risks under-dosing the transgene; you could get "safe but doesn't work," which is also thesis-ending. (3) KRESLADI is a rounding error commercially — management explicitly guides no material near-term revenue; do not model it as a revenue engine, so the equity is almost entirely Danon-optionality. (4) Chronic dilution — ~$40–48M/qtr burn, huge SBC, and a history of equity raises means holders get diluted over time even with the current runway. (5) Litigation overhang — unquantified securities/derivative exposure.
Pre-mortem (it's 18 months out and the thesis broke — what happened?): The 2H-2026 Danon cohort produced either a second complement-mediated SAE or a clean-but-flat efficacy readout at the lower dose; the FDA demanded a redesign; the stock round-tripped back toward/below net cash; management burned the PRV cash extending a now-doubtful program and had to raise dilutive equity into a broken narrative. The platform-safety doubt bled into RP-A601/RP-A701 and the whole "cardiac gene-therapy franchise" story collapsed to "a cash box with an ultra-rare approved drug."
Are multiples too high? No — there are no multiples to be too high; the stock trades near net cash, so on conventional terms it is cheap. The risk is not overvaluation, it's that "cheap on net cash" is exactly what a pre-binary-readout biotech looks like right before the readout resolves the option to zero or to multiples.
Contrarian view (what the market refuses to see): The market is treating RCKT as permanently impaired by the 2025 death and is ignoring that (a) the balance sheet was rebuilt to fortress levels non-dilutively, (b) the FDA already re-approved dosing after concluding the death was caused by a specific, now-removed component, and (c) a company with an approved product + a monetizable-PRV machine + net cash ≈ stock price is being priced as if the pipeline is worthless. If the 2H-2026 readout is clean, the gap between "priced for death" and "only-in-class curative asset with runway to 2028" is large.
Dismantling the bull case. What structurally breaks how this makes money: it doesn't make money — it makes net losses, and the entire equity value rests on a single Phase 2 cohort in a program that already produced a fatality. Where is the value concentrated? ~All of it in RP-A501 (Danon); KRESLADI is de-minimis revenue, and A601/A701 are early Phase 1 with the same platform-safety exposure. Why is the moat weaker than bulls think? The IP is licensed-in and royalty-taxed (RGNX takes high-single-to-low-teens royalties + 20% of any PRV proceeds; UCSD/CIEMAT/Temple layer on more), the manufacturing "moat" is a fixed-cost plant with a finance lease, and the scientific moat is one bad safety readout from evaporating. Most dangerous competitor bulls underestimate: not a direct Danon rival (there is none) but the category risk — the broader AAV-cardiac field (Tenaya, Lexeo) and the sector's regulatory scars (Sarepta's Elevidys troubles) mean a single high-profile AAV cardiac safety event anywhere raises the FDA bar for everyone, including Rocket. Worst capital-allocation / governance moves: a $1.44B accumulated deficit; a protocol change that killed a patient and wasn't disclosed before the death; RTW concentration with the CEO doubling as an RTW Venture Partner (whose interests dominate the register and the financing decisions); SBC that dilutes public holders while the founder holds ~1%. What must hold for today's price? That the ~$322.6M cash isn't burned on a failing program and that the 2H-2026 readout is at least safe. If growth/data disappoint by 20–30%? There is no "growth" to disappoint — the readout is binary; a bad safety signal likely takes the equity toward net-cash-minus-litigation, and a subsequent dilutive raise compounds it. Single scenario that permanently impairs the business: a second treatment-related death or severe complement SAE in the re-dosed Danon cohort → program halt + platform-wide safety doubt + FDA redesign demand. Plausibility: non-trivial — this is a therapy with a demonstrated capacity to cause fatal complement-mediated toxicity, now being re-dosed in critically ill patients.
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
A rare profitable, debt-free genomic-dx compounder (FY25 16% rev growth, $126M FCF) — but the stock has doubled into a 6.5x-sales / ~30x-FCF valuation just as Natera's FDA-approved Signatera CDx occupies the exact MIBC beachhead TrueMRD is launching into. Quality business, priced for flawless MRD execution it has not yet proven. WATCHING; would buy a reimbursement/launch-driven pullback under ~$40.
A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding.